Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis

Fig. 4

Baseline MRSS correlation and change during treatment with HICS for selected proteins. Individual patient data is shown for key serum proteins identified as significantly increasing during the 26-week treatment phase of the placebo-controlled trial. The panels compare changes in the HICS-treated or control extended dataset over 26 weeks that extend the data included in Table 1 for the placebo-controlled phase of the study. Adjacent plots show the change in the extended 52-week dataset for cases that moved from placebo to HICS at 26 weeks. These findings confirm the clear pattern of upregulation for PIIINP (a), αMSH (b), and ACTH (c). There is a trend for increase in bFGF (d) whilst the mean levels for COMP (e), TGFβ1 (f), and MCP1 (g) shows a fall over 26 weeks with HICS treatment. Changes in these key analytes also demonstrate the heterogeneity of the groups consistent with the heat maps shown above, with some subjects being obvious outliers and only some cases showing increase in serum levels after moving from placebo to HICS treatment at 26 weeks. HICS hyperimmune caprine serum

Back to article page